A novel fusion gene as a responsible factor for gastric cancer

摘要

Identifying a mutation that can be an index for predicting the effectiveness of treatment with a drug in cancer such as gastric cancer, providing a means for detecting the mutation, a gene having the mutation based on the mutation, or encoded by the same To provide a means of identifying cancer patients or subjects who are at risk for cancer for which a protein-targeting drug provides a therapeutic effect. A method for detecting gene fusion that is a responsible mutation (driver mutation) of cancer, comprising an ATG3-EPHB1 fusion polynucleotide, a TNIK-RNF123 fusion polynucleotide, or a SLC12A2-NRG2 fusion polynucleotide in an isolated sample derived from a subject Detecting a fusion polynucleotide of any of the above or a polypeptide encoded thereby.